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group (67% vs. 41%, p0.01). In particular this difference stemmed from an increase of
access site-related bleeding (21% vs. 7%, p0.01) and cardiac death (41% vs. 25%,
p0.01) in the FF group. The adjusted multivariable regression analysis confirmed radial
approach as independent outcome predictor (OR 0.53 CI 95% 0.29-0.96, p0.037).
Conclusions: Transradial approach use for PCI requiring IABP support positively
impacts periprocedural outcome by means of a significant access-site-related bleeding and
cardiac death prevention. Thus, its use seems strongly recommended in patients at
increased risk of bleeding, such as those admitted for an ACS.
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Background: There has been a significant increase in use of transradial access (TRA) for
PCI in the UK. Early on in the TRA learning curve, procedures are associated with more
catheter exchanges, longer screening times and with more contrast use. These factors are
all associated with increased risk of periprocedural neurological complications (NC).
Using the British Cardiovascular Intervention Society PCI database we assessed changes in
NC through a period of transition during which radial access became the dominant access for
PCI.
Methods: This study includes data collected by the British Cardiovascular Intervention
Society under the auspices of the Central Cardiac Audit Database. We performed a
retrospective analysis of the BCIS database between January 2006 and December 2010.
The data was split into 2 cohorts based on access site: either radial or femoral (mixed
access site use and other access sites were excluded from the analysis). A NC was defined
as a periprocedural TIA, ischemic stroke or hemorrhagic stroke.
Results: Between 2006 and 2010 a total of 348,092 procedures were recorded exclusively
using either transradial (TRA) or tansfemoral (TFA) access. Over 5 years, the use of TRA for
PCI increased from 17.1% to 50.8% of procedures. There was no difference in the incidence
of NC during this period. Following multivariate analysis of the whole 5 year cohort, no
difference in NC was observed between TRA and TFA (HR 1.005 CI 0.81-1.248: p0.96).
Conclusions: These results are reassuring and suggest that a switch from TFA to TRA
is not associated with any increased risk of periprocedural neurological complications.
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Background: The everolimus-eluting Bioresorbable Vascular Scaffold (Absorb) is a
novel approach to treating coronary lesions. A persistent inflammatory response, fibrin
deposition and delayed endothelialisation have been reported with overlapping first-
generation drug eluting stents. We report optical coherence tomography and histological
findings in a porcine coronary artery model after implantation of overlapping Absorb or
second-generation everolimus-eluting metallic platform stents (XIENCE V [XV]).
Methods: 41 overlapping Absorb and overlapping XV devices (3.012 mm) were
implanted in the main coronary arteries of 17 non-atherosclerotic pigs with a balloon
artery ratio of 1.1:1 (10% over-stretch). Implanted coronary arteries were evaluated by
OCT at 28 (Absorb: n11, XV: n 7) and 90 days (Absorb: n11, XV: n 8), with
immediate histological evaluation following euthanasia at the same time points. One
animal from each time point was evaluated with scanning electron microscopy alone.
Results: 1407 cross-sections were analysed by OCT and 148 cross-sections analysed
histologically. At 28 days in the overlap, OCT analyses indicated 80.1% of Absorb struts
and 99.4% of XV struts to be covered (p0.0001), corresponding to histological
observations of struts with cellular coverage of 75.4% and 99.6% respectively (p0.001).
Uncovered struts were almost exclusively related to the presence of ’stacked’ Absorb
struts, i.e. with a direct overlay configuration. At 90 days overlapping Absorb and
overlapping XV struts demonstrated99% strut coverage by OCT and histology, with no
evidence of a significant inflammatory process, and comparable % volume obstructions.
Conclusions: In porcine coronary arteries implanted with overlapping Absorb, strut
coverage is dependent on the overlay configuration of Absorb struts at 28 days and not at
90 days. The potential clinical implications of increased strut thickness in the management
of long lesions & coronary bifurcations may have important clinical (e.g. duration of
antiplatelet therapy) and design considerations (e.g. longer devices & the requirement of
dedicated bifurcation devices to avoid overlapping the device) for current and future
devices with bioresorbable platforms.
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Background: The safety and performance of the Absorb Bioresorbable Vascular
Scaffold (BVS) System (Abbott Vascular, Santa Clara, CA) has been previously
established in 131 patients from Cohort A and Cohort B of the First-in-Man ABSORB
trial. Results out to 2 years have been presented in 101 patients from the ABSORB Cohort
B trial. At 12 months, the MACE rate was 6.9%, with no scaffold thrombosis reported,
which was sustained out to 2 years with a MACE rate of 9.0%. Following this trial,
ABSORB EXTEND was initiated as a global continued access study (outside of the US)
to expand experience with the Absorb BVS to different geographies. Additionally, patients
were treated for longer coronary lesions than those in the ABSORB trial using either
longer scaffold lengths or planned overlap of the Absorb BVS.
Methods: ABSORB EXTEND is a prospective, single-arm, open-label clinical study that
is planning to enroll up to 1,000 subjects at up to 100 sites. Included are patients with
lesions  28 mm in length and reference vessel diameter of 2.0 - 3.3 mm (as assessed by
on-line QCA or IVUS). Treatment of a maximum of two de novo native coronary artery
lesions, each in a different epicardial vessel, is permitted.
Results: Interim 12-month data in the first 250 patients enrolled in ABSORB EXTEND
will be available for the first time in October 2012 and will provide additional data on the
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